GlassScriptPhysician profile
Robyn G Young
NPI 1396775979
$11,040.94
in general payments reported to CMS, 2019-2025
51 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,209 · 2020: $1,139 · 2021: $911 · 2022: $1,934 · 2023: $1,808 · 2024: $1,805 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,846.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $937.22 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $864.79 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Catalyst Pharmaceuticals, INC. | $667.94 | 2021-2025 | Fycompa |
| Emd Serono, INC. | $662.37 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $606.96 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Amgen INC. | $571.61 | 2019-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $547.10 | 2019-2024 | Ocrevus, Enspryng |
| Neurocrine Biosciences, INC. | $500.49 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $478.36 | 2019-2024 | Ubrelvy, Duopa, Botox |
| Akcea Therapeutics, INC. | $353.82 | 2019-2020 | |
| Celgene Corporation | $334.51 | 2023-2025 | Zeposia |
| Pfizer INC. | $306.16 | 2023-2025 | |
| Horizon Therapeutics Plc | $272.14 | 2022-2023 | Uplizna |
| Acorda Therapeutics, INC | $244.44 | 2019-2023 | Inbrija |
| Janssen Pharmaceuticals, INC | $233.73 | 2021-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robyn Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.